Pulsed Field Ablation (PFA) is emerging as a game-changer in treating atrial fibrillation and other heart rhythm disorders. Unlike traditional thermal methods, PFA uses non-thermal energy to create precise lesions, minimizing the risk of collateral damage. Several medtech giants are accelerating PFA innovation, each positioning to lead in this next-generation field.
Boston Scientific, through Farapulse, has pioneered PFA with a non-thermal system that’s gaining strong clinical and regulatory momentum. Meanwhile, Medtronic’s acquisition of Affera is expanding its reach, advancing novel catheter-based PFA solutions now in trials. Johnson & Johnson’s Biosense Webster division is developing Varipulse—an integrated system aimed at enhancing safety and precision in AFib treatments. Abbott is also entering the race with Volt, a next-gen PFA platform now in clinical testing, promising high precision and minimal invasiveness.
Biotronik, with its Centauri system, is gaining traction in Europe through a strategic distribution deal with CardioFocus. Centauri’s customizable monopolar waveform and focal contact force approach position it as a serious contender for widespread clinical adoption.
These companies are shaping what could become the new gold standard in electrophysiology. Who do you think will lead the PFA revolution over the next 5 years?
Follow MEDWIRE.AI for pulse-checks on MedTech breakthroughs.
